查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1587794

淋巴瘤治疗市场规模、份额、趋势分析报告：2025-2030 年按类型、药物、地区和细分市场预测

Lymphoma Treatment Market Size, Share & Trends Analysis Report By Type (Hodgkin Lymphoma, Non-Hodgkin Lymphoma), By Drugs (Adcetris, Opdivo, Rituxan, Imbruvica, Keytruda), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

淋巴瘤治疗市场的成长与趋势：

Grand View Research, Inc.最新报告显示，预计2030年全球淋巴瘤治疗市场规模将达119.7亿美元，2025年至2030年复合年增长率为8.3%。

开发新治疗方法和扩大产品阵容的研究活动的活性化可能会推动成长。新药商业化的增加预计将进一步推动成长。

多种产品的出现预计将进一步促进成长。例如，2019年1月，百济神州的治疗成人套细胞淋巴瘤的产品Zanubrutinib获得美国FDA突破性疗法认定。该药物目前正处于后期临床试验阶段，预计将在预测期内上市。

医疗保健专业人员和患者对淋巴瘤早期诊断的认识不断提高，以及政府对研发的资助不断增加，预计将推动市场成长。例如，美国癌症研究所等研究机构获得美国国会的资助，以支持与癌症相关的研究和相关活动。

淋巴瘤治疗市场报告亮点

  • 非何杰金氏淋巴瘤(NHL) 占据市场主导地位，到 2024 年，其销售份额将达到 86.2%，预计在未来几年，由于 NHL 盛行率不断上升，病例数将大幅增加。
  • 由于诊断病例数量的增加以及促进早期检测的诊断技术的进步，预计何杰金氏淋巴瘤(HL) 在预测期内将以 15.7% 的复合年增长率增长。
  • Rituxan（MabThera）占据市场主导地位，2024 年占据最大销售份额，为 28.8%。这是由于其已确定的功效并广泛用于多种适应症，尤其是非非何杰金氏淋巴瘤(NHL)。
  • Keytruda 预计在预测期内以 18.9% 的复合年增长率增长最快，因为它是一种领先的免疫疗法选择，特别是对于晚期或难治性病例。
  • 医院药局占据市场主导地位，2024 年销售份额最大，为 36.1%。
  • 北美淋巴瘤治疗市场主导全球市场，2024年占最大销售量49.0%，这是由于淋巴瘤病例，尤其非何杰金氏淋巴瘤的高盛行率。
  • 由于发病率上升和医疗保健支出增加，亚太地区淋巴瘤治疗市场预计将快速成长。该地区国家的医疗基础设施正在改善，创新治疗方法也不断改善。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章淋巴瘤治疗市场变数、趋势与范围

  • 市场体系展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 营商环境分析
    • 产业分析-波特五力分析
    • PESTLE分析

第四章 淋巴瘤治疗市场：药物评估与趋势分析

  • 细分仪表板
  • 淋巴瘤治疗市场：2024 年和 2030 年药物变化分析
  • 何杰金氏淋巴瘤
  • 非何杰金氏淋巴瘤

第五章淋巴瘤治疗市场：药物评估与趋势分析

  • 细分仪表板
  • 淋巴瘤治疗市场：2024 年和 2030 年药物变化分析
  • Rituxan/MabThera
  • Revlimid
  • 伊布鲁维察
  • ADCETRIS
  • 密钥楚达
  • Opdivo
  • 其他的

第六章 淋巴瘤治疗市场：通路估计与趋势分析

  • 细分仪表板
  • 淋巴瘤治疗市场：2024 年和 2030 年分销管道变化分析
  • 医院药房
  • 零售药房
  • 专业药房
  • 其他的

第七章淋巴瘤治疗市场：区域估计与趋势分析

  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 2018-2030年市场规模、预测趋势分析：
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 南非
    • 阿拉伯聯合大公国

第八章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • Bristol-Myers Squibb Company
    • Celgene Corporation
    • Merck &Co., Inc.
    • F. Hoffmann-La Roche Ltd
    • Seattle Genetics, Inc.
    • Takeda Pharmaceutical Company Ltd
    • Johnson &Johnson
    • Eli Lilly and Company
    • AstraZeneca
    • Novartis AG
Product Code: GVR-3-68038-983-8

Lymphoma Treatment Market Growth & Trends:

The global lymphoma treatment market size is expected to reach USD 11.97 billion by 2030, registering a CAGR of 8.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. Rising research activities for development of new treatments and increasing product line extension are likely to expedite growth. Increasing commercialization of novel drugs are further expected to drive the growth.

Availability of wide variety of products is further expected to aid growth. For instance, in January 2019, BeiGene received a breakthrough therapy designation by the U.S. FDA for its product Zanubrutinib for treating mantle cell lymphoma in adults. This drug is currently in late-stage clinical trial and is expected to be launched during the forecast period.

Growing awareness about early diagnosis of lymphoma among healthcare professionals & patients and rising government funding for R&D are some factors expected to propel market growth. For instance, institutes such as National Cancer Institute receives funding from the U.S. Congress to support cancer-related research and associated activities.

Lymphoma Treatment Market Report Highlights:

  • Non-Hodgkin Lymphoma (NHL) dominated the market with the largest revenue share of 86.2% in 2024, driven by the increasing incidence of NHL, with projections indicating a significant rise in cases over the coming years.
  • Hodgkin Lymphoma (HL) is expected to grow at a CAGR of 15.7% over the forecast period attributed to a rising number of diagnosed cases and advancements in diagnostic technologies that facilitate earlier detection.
  • Rituxan (MabThera) dominated the market and accounted for the largest revenue share of 28.8% in 2024, attributed to its established efficacy and broad usage across various indications, particularly non-Hodgkin lymphoma (NHL).
  • Keytruda is expected to grow at the fastest CAGR of 18.9% over the forecast period, owing to its status as a leading immunotherapy option, particularly for advanced or refractory cases.
  • Hospital pharmacies dominated the market and accounted for the largest revenue share of 36.1% in 2024 attributed to the increasing prevalence of lymphoma cases requiring specialized care.
  • The lymphoma treatment market in North America dominated the global market and accounted for the largest revenue share of 49.0% in 2024, owing to the high prevalence of lymphoma cases, particularly non-Hodgkin lymphoma, which accounts for a significant portion of cancer diagnoses.
  • The Asia Pacific lymphoma treatment market is projected to grow rapidly due to rising incidence rates and increasing healthcare spending. Countries in this region are experiencing improvements in healthcare infrastructure and access to innovative treatments

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Drug
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Lymphoma Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrant
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Lymphoma Treatment Market: Drug Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Lymphoma Treatment Market: Drug Movement Analysis, 2024 & 2030 (USD Million)
  • 4.3. Hodgkin Lymphoma
    • 4.3.1. Hodgkin Lymphoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Non-Hodgkin Lymphoma
    • 4.4.1. Non-Hodgkin Lymphoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Lymphoma Treatment Market: Drug Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Lymphoma Treatment Market: Drug Movement Analysis, 2024 & 2030 (USD Million)
  • 5.3. Rituxan/MabThera
    • 5.3.1. Rituxan/MabThera Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Revlimid
    • 5.4.1. Revlimid Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Imbruvica
    • 5.5.1. Imbruvica Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Adcetris
    • 5.6.1. Adcetris Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Keytruda
    • 5.7.1. Keytruda Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8. Opdivo
    • 5.8.1. Opdivo Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.9. Others
    • 5.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Lymphoma Treatment Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Lymphoma Treatment Market: Distribution Channel Movement Analysis, 2024 & 2030 (USD Million)
  • 6.3. Hospital Pharmacy
    • 6.3.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Retail Pharmacy
    • 6.4.1. Retail Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Specialty Pharmacy
    • 6.5.1. Specialty Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Lymphoma Treatment Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework
      • 7.4.2.3. Competitive Insights
      • 7.4.2.4. U.S. Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework
      • 7.4.3.3. Competitive Insights
      • 7.4.3.4. Canada Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework
      • 7.5.2.3. Competitive Insights
      • 7.5.2.4. UK Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework
      • 7.5.3.3. Competitive Insights
      • 7.5.3.4. Germany Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework
      • 7.5.4.3. Competitive Insights
      • 7.5.4.4. France Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Regulatory Framework
      • 7.5.5.3. Competitive Insights
      • 7.5.5.4. Italy Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Regulatory Framework
      • 7.5.6.3. Competitive Insights
      • 7.5.6.4. Spain Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework
      • 7.6.2.3. Competitive Insights
      • 7.6.2.4. Japan Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Framework
      • 7.6.3.3. Competitive Insights
      • 7.6.3.4. China Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Framework
      • 7.6.4.3. Competitive Insights
      • 7.6.4.4. India Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Framework
      • 7.6.5.3. Competitive Insights
      • 7.6.5.4. South Korea Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.6.6. Australia
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Regulatory Framework
      • 7.6.6.3. Competitive Insights
      • 7.6.6.4. Australia Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Regulatory Framework
      • 7.7.2.3. Competitive Insights
      • 7.7.2.4. Brazil Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Regulatory Framework
      • 7.7.3.3. Competitive Insights
      • 7.7.3.4. Argentina Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. MEA Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Regulatory Framework
      • 7.8.2.3. Competitive Insights
      • 7.8.2.4. South Africa Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. UAE
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Regulatory Framework
      • 7.8.3.3. Competitive Insights
      • 7.8.3.4. UAE Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Bristol-Myers Squibb Company
      • 8.4.1.1. Overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Celgene Corporation
      • 8.4.2.1. Overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Merck & Co., Inc.
      • 8.4.3.1. Overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. F. Hoffmann-La Roche Ltd
      • 8.4.4.1. Overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Seattle Genetics, Inc.
      • 8.4.5.1. Overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Takeda Pharmaceutical Company Ltd
      • 8.4.6.1. Overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Johnson & Johnson
      • 8.4.7.1. Overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Eli Lilly and Company
      • 8.4.8.1. Overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. AstraZeneca
      • 8.4.9.1. Overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. Novartis AG
      • 8.4.10.1. Overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Lymphoma Treatment Market, by Region, 2018 - 2030 (USD Million)
  • Table 4 Global Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 5 Global Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 6 Global Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 7 North America Lymphoma Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 8 North America Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 9 North America Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 10 North America Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 11 U.S Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 12 U.S Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 13 U.S Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 14 Canada Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 15 Canada Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 16 Canada Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 17 Mexico Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 18 Mexico Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 19 Mexico Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 20 Europe Lymphoma Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 21 Europe Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 22 Europe Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 23 Europe Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 24 UK Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 25 UK Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 26 UK Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 27 Germany Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 28 Germany Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 29 Germany Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 30 France Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 31 France Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 32 France Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 33 Italy Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 34 Italy Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 35 Italy Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 36 Spain Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 37 Spain Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 38 Spain Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 39 Asia Pacific Lymphoma Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 43 Japan Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 44 Japan Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 45 Japan Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 46 China Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 47 China Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 48 China Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 49 India Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 50 India Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 51 India Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 52 Australia Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 53 Australia Lymphoma Treatment Market, by portability, 2018 - 2030 (USD Million)
  • Table 54 Australia Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 55 Australia Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 56 South Korea Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 57 South Korea Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 58 South Korea Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 59 Latin America Lymphoma Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 60 Latin America Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 61 Latin America Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 62 Latin America Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 63 Brazil Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 64 Brazil Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 65 Brazil Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 66 Argentina Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 67 Argentina Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 68 Argentina Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 69 Middle East & Africa Lymphoma Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 70 Middle East & Africa Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 71 Middle East & Africa Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 72 Middle East & Africa Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 73 South Africa Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 74 South Africa Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 75 South Africa Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 76 UAE Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 77 UAE Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 78 UAE Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Lymphoma treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Product and type outlook (USD Million)
  • Fig. 10 Type, drug, and distribution channel outlook
  • Fig. 11 Competitive landscape
  • Fig. 12 Lymphoma treatment market dynamics
  • Fig. 13 Lymphoma treatment market: Porter's five forces analysis
  • Fig. 14 Lymphoma treatment market: PESTLE analysis
  • Fig. 15 Lymphoma treatment market: Type segment dashboard
  • Fig. 16 Lymphoma treatment market: Type market share analysis, 2024 & 2030
  • Fig. 17 Hodgkin lymphoma market, 2018 - 2030 (USD Million)
  • Fig. 18 Non-Hodgkin lymphoma market, 2018 - 2030 (USD Million)
  • Fig. 19 Lymphoma treatment market: Drug segment dashboard
  • Fig. 20 Lymphoma treatment market: Drug market share analysis, 2024 & 2030
  • Fig. 21 Adcetris market, 2018 - 2030 (USD Million)
  • Fig. 22 Opdivo market, 2018 - 2030 (USD Million)
  • Fig. 23 Rituxan/MabThera market, 2018 - 2030 (USD Million)
  • Fig. 24 Imbruvica market, 2018 - 2030 (USD Million)
  • Fig. 25 Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 26 Revlimid market, 2018 - 2030 (USD Million)
  • Fig. 27 Others market, 2018 - 2030 (USD Million)
  • Fig. 28 Lymphoma treatment market: Distribution Channel segment dashboard
  • Fig. 29 Lymphoma treatment market: Distribution Channel market share analysis, 2024 & 2030
  • Fig. 30 Hospital pharmacy market, 2018 - 2030 (USD Million)
  • Fig. 31 Retail pharmacy market, 2018 - 2030 (USD Million)
  • Fig. 32 Specialty pharmacy market, 2018 - 2030 (USD Million)
  • Fig. 33 Lymphoma treatment market revenue, by region
  • Fig. 34 Regional marketplace: Key takeaways
  • Fig. 35 Regional marketplace: Key takeaways
  • Fig. 36 North America lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 37 U.S. country dynamics
  • Fig. 38 U.S. lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 39 Canada country dynamics
  • Fig. 40 Canada lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 41 Mexico country dynamics
  • Fig. 42 Mexico lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 43 Europe lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 44 UK country dynamics
  • Fig. 45 UK lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 46 Germany country dynamics
  • Fig. 47 Germany lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 48 France country dynamics
  • Fig. 49 France lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 50 Italy country dynamics
  • Fig. 51 Italy lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 52 Spain country dynamics
  • Fig. 53 Spain lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 54 Norway country dynamics
  • Fig. 55 Norway lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 56 Sweden country dynamics
  • Fig. 57 Sweden lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 58 Denmark country dynamics
  • Fig. 59 Denmark lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 60 Asia Pacific lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 61 Japan country dynamics
  • Fig. 62 Japan lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 63 China country dynamics
  • Fig. 64 China lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 65 India country dynamics
  • Fig. 66 India lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 67 Australia country dynamics
  • Fig. 68 Australia lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 69 South Korea country dynamics
  • Fig. 70 South Korea lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 71 Thailand country dynamics
  • Fig. 72 Thailand lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 73 Latin America lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 74 Brazil country dynamics
  • Fig. 75 Brazil lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 76 Argentina country dynamics
  • Fig. 77 Argentina lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 78 MEA lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 79 South Africa country dynamics
  • Fig. 80 South Africa lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 81 Saudi Arabia country dynamics
  • Fig. 82 Saudi Arabia lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 83 UAE country dynamics
  • Fig. 84 UAE lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 85 Kuwait Key country dynamics
  • Fig. 86 Kuwait lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 87 Company categorization
  • Fig. 88 Company market position analysis
  • Fig. 89 Strategic framework